Xeris Biopharma Holdings, Inc. revised revenue guidance for the year 2023. For the year, the company expects to report total revenue at the high end of its previous guidance of $160 million to $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +2.94% | +0.57% | -25.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.53% | 259M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Year 2023